Last updated: January 26, 2026
Sponsor: Eli Lilly and Company
Overall Status: Active - Enrolling
Phase
N/A
Condition
Schizotypal Personality Disorder (Spd)
Tourette's Syndrome
Mood Disorders
Treatment
N/AClinical Study ID
NCT01088386
12991
F1D-MC-B041
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Any patients receiving Zyprexa Relprevv enrolled in Zyprexa Relprevv Patient CareProgram
Exclusion
Exclusion Criteria:
- Any patient not receiving Zyprexa Relprevv
Study Design
Total Participants: 4000
Study Start date:
March 03, 2010
Estimated Completion Date:
June 30, 2026
Study Description
Connect with a study center
United BioSource Corporation
Blue Bell, Pennsylvania 19422
United StatesSite Not Available
United BioSource Corporation
Blue Bell 5180961, Pennsylvania 6254927 19422
United StatesSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.